Peer-reviewed veterinary case report
New treatment using laminin shows promise for dogs
By Chize, Carolina de Miranda et al.·Published in Frontiers in veterinary science·2025·Institute of Biomedical Sciences, Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A laminin-based therapy for dogs with chronic spinal cord injury: promising results of a longitudinal trial.
- Species:
- dog
Plain-English summary
A group of six paraplegic dogs with severe spinal cord injuries, either from trauma or disc degeneration, received a new treatment called polylaminin to see if it could improve their ability to walk. Over six months, their walking scores showed significant improvement, indicating that the treatment was effective. The dogs were also given physiotherapy and monitored closely for safety, with no serious side effects reported. This study suggests that polylaminin, especially when combined with other therapies, could be a promising option for dogs with chronic spinal cord injuries.
People also search for: dog spinal cord injury treatment · polylaminin for dogs · improving dog walking after injury
Abstract
INTRODUCTION: Polylaminin, an improved form of the natural protein laminin, has been shown to promote axonal regeneration and functional recovery in animal models of acute spinal cord injury (SCI), and is safe and potentially beneficial in humans when administered within the first days after traumatic SCI. This study aimed to evaluate the effect of polylaminin in dogs with chronic SCI. METHODS: We conducted a prospective, longitudinal study in six paraplegic dogs with severe chronic thoracolumbar SCI (T3-L3) caused by trauma ( = 2) or disc degeneration ( = 4). The study assessed whether gait scores, measured during an extended screening period (at least 4 months), would improve during the follow-up (6 months). Polylaminin was delivered intraspinally at a dose of 1 μg/kg, in combination with either glial-derived neurotrophic factor (GDNF; Group 1; = 3) or chondroitinase ABC (Group 2; = 3). Safety was assessed through neurological examinations, blood tests and monitoring of medical complications. Gait analysis was carried out using the Texas Spinal Cord Injury Scale (TSCIS) and the Open Field Scale (OFS), while a linear mixed model was used for statistical analysis. During the screening period, dogs received physiotherapy twice per week and had their gait scored periodically. The first six dogs whose scores had remained stable across three evaluations were enrolled. After owners provided informed consent, dogs were randomly allocated to either treatment group. RESULTS: No neurological deterioration, serious clinical events or notable deviations in blood tests were observed. The TSCIS average baseline score increased from 2.2 to 3.2 (95% CI: 0.77-1.2; < 0.001), while the OFS score increased from 1.5 to 3.1 (95% CI: 1.3-1.9; < 0.001). DISCUSSION: Although the present study could not discriminate between the benefits of the two treatments, our findings suggest that polylaminin, in combination with GDNF or chondroitinase ABC, is a safe and potentially effective treatment, which underscores the relevance of further studies to establish a new approach to improving gait function in dogs with chronic SCI.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40881640/